Why the study?
Does mineralocorticoid receptor antagonist (MRA) therapy improve cardiac structure and function in patients with asymptomatic diastolic dysfunction or HFpEF?
Does mineralocorticoid receptor antagonist (MRA) therapy improve cardiac structure and function in patients with asymptomatic diastolic dysfunction or HFpEF?
MRA therapy improves surrogate markers of diastolic function and cardiac fibrosis in patients with asymptomatic diastolic dysfunction or HFpEF.
MRA surrogate benefits in HFpEF support dedicated outcome trials; insufficient evidence precludes practice change.
MRA therapy in patients with asymptomatic diastolic dysfunction or HFPEF is associated with significant improvement in diastolic function and markers of cardiac fibrosis without a significant change in LV mass or dimensions.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: